CEACAM5 and colorectal cancer: Currently, a phase I clinical trial (NCT02349724) is underway to evaluate the safety and efficacy of CEA-targeting chimeric antigen receptor T cells (CEA-TCB) in combination with atezolizumab, an anti-PD-L1 antibody, for patients with advanced CEA-positive solid tumors, including colorectal cancer (6).